Literature DB >> 23334822

Personalizing medicine for autoimmune and inflammatory diseases.

Andrew C Chan1, Timothy W Behrens.   

Abstract

Therapies that target molecular pathways do not provide uniform benefits for all patients at present. New transformative therapies for autoimmune and inflammatory diseases require greater molecular understanding of patient subsets and the ability to personalize targeted therapies for each subset.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23334822     DOI： 10.1038/ni.2473

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


  19 in total

1.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

2.  T-helper type 2-driven inflammation defines major subphenotypes of asthma.

Authors:  Prescott G Woodruff; Barmak Modrek; David F Choy; Guiquan Jia; Alexander R Abbas; Almut Ellwanger; Laura L Koth; Joseph R Arron; John V Fahy
Journal:  Am J Respir Crit Care Med       Date:  2009-05-29       Impact factor: 21.405

Review 3.  Asthma phenotypes: the evolution from clinical to molecular approaches.

Authors:  Sally E Wenzel
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

Review 4.  The intestinal microbiota in inflammatory bowel diseases: time to connect with the host.

Authors:  Harry Sokol; Philippe Seksik
Journal:  Curr Opin Gastroenterol       Date:  2010-07       Impact factor: 3.287

5.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

6.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

7.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Authors:  Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682

8.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

9.  Common variants at five new loci associated with early-onset inflammatory bowel disease.

Authors:  Marcin Imielinski; Robert N Baldassano; Anne Griffiths; Richard K Russell; Vito Annese; Marla Dubinsky; Subra Kugathasan; Jonathan P Bradfield; Thomas D Walters; Patrick Sleiman; Cecilia E Kim; Aleixo Muise; Kai Wang; Joseph T Glessner; Shehzad Saeed; Haitao Zhang; Edward C Frackelton; Cuiping Hou; James H Flory; George Otieno; Rosetta M Chiavacci; Robert Grundmeier; Massimo Castro; Anna Latiano; Bruno Dallapiccola; Joanne Stempak; Debra J Abrams; Kent Taylor; Dermot McGovern; Gary Silber; Iwona Wrobel; Antonio Quiros; Jeffrey C Barrett; Sarah Hansoul; Dan L Nicolae; Judy H Cho; Richard H Duerr; John D Rioux; Steven R Brant; Mark S Silverberg; Kent D Taylor; M Michael Barmuda; Alain Bitton; Themistocles Dassopoulos; Lisa Wu Datta; Todd Green; Anne M Griffiths; Emily O Kistner; Michael T Murtha; Miguel D Regueiro; Jerome I Rotter; L Philip Schumm; A Hillary Steinhart; Stephen R Targan; Ramnik J Xavier; Cécile Libioulle; Cynthia Sandor; Mark Lathrop; Jacques Belaiche; Olivier Dewit; Ivo Gut; Simon Heath; Debby Laukens; Myriam Mni; Paul Rutgeerts; André Van Gossum; Diana Zelenika; Denis Franchimont; J P Hugot; Martine de Vos; Severine Vermeire; Edouard Louis; Lon R Cardon; Carl A Anderson; Hazel Drummond; Elaine Nimmo; Tariq Ahmad; Natalie J Prescott; Clive M Onnie; Sheila A Fisher; Jonathan Marchini; Jilur Ghori; Suzannah Bumpstead; Rhian Gwillam; Mark Tremelling; Panos Delukas; John Mansfield; Derek Jewell; Jack Satsangi; Christopher G Mathew; Miles Parkes; Michel Georges; Mark J Daly; Melvin B Heyman; George D Ferry; Barbara Kirschner; Jessica Lee; Jonah Essers; Richard Grand; Michael Stephens; Arie Levine; David Piccoli; John Van Limbergen; Salvatore Cucchiara; Dimitri S Monos; Stephen L Guthery; Lee Denson; David C Wilson; Straun F A Grant; Mark Daly; Mark S Silverberg; Jack Satsangi; Hakon Hakonarson
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

10.  Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.

Authors:  Lynda Bennett; A Karolina Palucka; Edsel Arce; Victoria Cantrell; Josef Borvak; Jacques Banchereau; Virginia Pascual
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307
View more
  19 in total

1.  Tweaking the B lymphocyte compartment in autoimmune diseases.

Authors:  Moncef Zouali
Journal:  Nat Immunol       Date:  2014-03       Impact factor: 25.606

Review 2.  Neural regulation of immunity: molecular mechanisms and clinical translation.

Authors:  Valentin A Pavlov; Kevin J Tracey
Journal:  Nat Neurosci       Date:  2017-01-16       Impact factor: 24.884

3.  Reducing the risk of failure: biomarker-guided trial design.

Authors:  Michael J Townsend; Joseph R Arron
Journal:  Nat Rev Drug Discov       Date:  2016-07-15       Impact factor: 84.694

Review 4.  The IBD interactome: an integrated view of aetiology, pathogenesis and therapy.

Authors:  Heitor S P de Souza; Claudio Fiocchi; Dimitrios Iliopoulos
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

5.  Multivariate inference of pathway activity in host immunity and response to therapeutics.

Authors:  Gautam Goel; Kara L Conway; Martin Jaeger; Mihai G Netea; Ramnik J Xavier
Journal:  Nucleic Acids Res       Date:  2014-08-21       Impact factor: 16.971

Review 6.  Precision Medicine: A New Paradigm in Therapeutics.

Authors:  Neha Akhoon
Journal:  Int J Prev Med       Date:  2021-02-24

Review 7.  Solving the puzzle of autoimmunity: critical questions.

Authors:  Dawn E Smilek; E William St Clair
Journal:  F1000Prime Rep       Date:  2015-02-03

8.  The parasitic worm product ES-62 targets myeloid differentiation factor 88-dependent effector mechanisms to suppress antinuclear antibody production and proteinuria in MRL/lpr mice.

Authors:  David T Rodgers; Mairi A McGrath; Miguel A Pineda; Lamyaa Al-Riyami; Justyna Rzepecka; Felicity Lumb; William Harnett; Margaret M Harnett
Journal:  Arthritis Rheumatol       Date:  2015-04       Impact factor: 10.995

Review 9.  Restoring the balance: immunotherapeutic combinations for autoimmune disease.

Authors:  Dawn E Smilek; Mario R Ehlers; Gerald T Nepom
Journal:  Dis Model Mech       Date:  2014-05       Impact factor: 5.758

10.  Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.

Authors:  Glynn Dennis; Cécile T J Holweg; Sarah K Kummerfeld; David F Choy; A Francesca Setiadi; Jason A Hackney; Peter M Haverty; Houston Gilbert; Wei Yu Lin; Lauri Diehl; S Fischer; An Song; David Musselman; Micki Klearman; Cem Gabay; Arthur Kavanaugh; Judith Endres; David A Fox; Flavius Martin; Michael J Townsend
Journal:  Arthritis Res Ther       Date:  2014-04-30       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.